Olanzapine 5 mg for Nausea and Vomiting in Patients with Nasopharyngeal Carcinoma Receiving Cisplatin-Based Concurrent Chemoradiotherapy

Table 2

The complete response and no nausea rate and in acute, delayed, and overall phase between two groups.

Variables	Olanzapine 5 mg	Olanzapine 10 mg
Acute phase (0-24 h)
Complete response	70 (93.3%)	71 (94.7%)	0.731
No nausea	57 (76%)	59 (78.7%)	0.697
Delayed phase (25–120 h)
Complete response	57 (76%)	59 (78.7%)	0.697
No nausea	41 (54.7%)	45 (60%)	0.509
Overall phase (0–120 h)
Complete response	55 (73.3%)	58 (77.3%)	0.570
No nausea	38 (50.7%)	43 (57.3)	0.111